Glaxosmithkline and yale university establish drug discovery collaboration to design potential new class of medicines Full Text
GlaxoSmithKline plc and Yale University have established a drug discovery research collaboration to design a potential new class of medicines that degrade disease–causing proteins. The collaboration combines GSK's expertise in medicinal chemistry with Yale's pioneering work on proteolysis targeting chimeric molecules or PROTACs. PROTAC technology guides disease–causing proteins to a cell's garbage disposal where they can be destroyed. Mutant or higher–than normal amounts of these proteins typically drive disease progression in areas such as oncology, inflammation and infections; yet many cannot be tackled by traditional ways of making drugs.